Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Quest Diagnostics (DGX) is 9/10.
Quest posted 9.2% revenue growth with 9% organic acceleration and adjusted EPS of $2.50 (up 15%), with operating margin expanding to 15.4%. FY2026 guidance was raised to $11.78-11.9 billion revenue and $10.63-10.83 EPS on strong Q1 momentum. AD-Detect Alzheimer's testing more than doubled, Fresenius and Corewell contributed to 7% organic volume, and AI-driven automation was enhancing productivity and patient engagement.
Scored from Quest Diagnostics’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.62B | +14.6% | $1.95 | +14.7% | 32.7% | 13.8% | 8.5% | $341M |
| FY2025 Q1 | $2.65B | +12.1% | $1.94 | +12.8% | 32.5% | 13.0% | 8.3% | $197M |
| FY2025 Q2 | $2.76B | +15.2% | $2.47 | +21.1% | 34.2% | 15.9% | 10.2% | $436M |
| FY2025 Q3 | $2.82B | +13.2% | $2.16 | +8.5% | 33.7% | 13.7% | 8.7% | $419M |
| FY2025 Q4 | $2.81B | +7.1% | $2.18 | +11.8% | 32.6% | 13.9% | 8.7% | $307M |
| FY2026 Q1 | $2.90B | +9.2% | $2.24 | +15.5% | 32.5% | 13.8% | 8.7% | $164M |
| FY2026 Q2 | $3.04B | +10.2% | $2.84 | +15.0% | 33.7% | 15.1% | 10.5% | $330M |